Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.25.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

​

​

​

​

​

​

​

​

​

    

Three Months Ended

​

​

March 31, 

​

March 31, 

​

    

2025

    

2024

Operating expenses:

​

​

​

​

​

​

Clinical

​

$

1,817,232

​

$

2,274

Chemical, manufacturing and controls

​

​

135,122

​

​

42,637

Research and preclinical

​

​

24,134

​

​

63,716

Regulatory

​

​

21,658

​

​

(16)

Other research and development costs

​

​

438,852

​

​

235,106

Total research and development

​

​

2,436,998

​

​

343,717

General and administrative expenses

​

​

1,992,928

​

​

970,384

Total operating expenses

​

$

4,429,926

​

$

1,314,101

Loss on debt conversion with related party

​

​

6,134,120

​

​

—

Interest expense (income), net

​

​

147,090

​

​

(22,766)

Exchange loss, net

​

 

23,274

​

 

—

Net loss before income taxes

​

$

10,734,410

​

$

1,291,335